WO2012127501A3 - Composition for improving endometrial thickness during ovarian stimulation - Google Patents

Composition for improving endometrial thickness during ovarian stimulation Download PDF

Info

Publication number
WO2012127501A3
WO2012127501A3 PCT/IN2012/000166 IN2012000166W WO2012127501A3 WO 2012127501 A3 WO2012127501 A3 WO 2012127501A3 IN 2012000166 W IN2012000166 W IN 2012000166W WO 2012127501 A3 WO2012127501 A3 WO 2012127501A3
Authority
WO
WIPO (PCT)
Prior art keywords
thickness during
ovarian stimulation
composition
highly purified
during ovarian
Prior art date
Application number
PCT/IN2012/000166
Other languages
French (fr)
Other versions
WO2012127501A2 (en
Inventor
Prasad K.V.S.
L. Soman JAY
Original Assignee
Sanzyme Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanzyme Limited filed Critical Sanzyme Limited
Publication of WO2012127501A2 publication Critical patent/WO2012127501A2/en
Publication of WO2012127501A3 publication Critical patent/WO2012127501A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

The present invention relates to a pharmaceutical composition comprising combination of highly purified Follicle Stimulating Hormone (FSH) and highly purified Human Chorionic Gonadotropin (HCG) for improving endometrial thickness during ovarian stimulation. Particularly, the invention also provides composition for improving endometrium thickness during ovarian stimulation comprising combination of 5 IU to 50 IU of highly purified FSH and 50 IU to 1000 IU of highly purified hCG per dosage and pharmaceutical formulations comprising the same.
PCT/IN2012/000166 2011-03-11 2012-03-12 Composition for improving endometrial thickness during ovarian stimulation WO2012127501A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN693/MUM/2011 2011-03-11
IN693MU2011 2011-03-11

Publications (2)

Publication Number Publication Date
WO2012127501A2 WO2012127501A2 (en) 2012-09-27
WO2012127501A3 true WO2012127501A3 (en) 2013-03-21

Family

ID=46879830

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2012/000166 WO2012127501A2 (en) 2011-03-11 2012-03-12 Composition for improving endometrial thickness during ovarian stimulation

Country Status (1)

Country Link
WO (1) WO2012127501A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2782584T (en) 2011-11-23 2021-09-02 Therapeuticsmd Inc Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
AR100562A1 (en) 2014-05-22 2016-10-12 Therapeuticsmd Inc PHARMACEUTICAL COMPOSITION OF ESTRADIOL AND PROGESTERONE FOR HORMONAL REPLACEMENT THERAPY
WO2016018993A1 (en) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CN110787286A (en) * 2019-11-21 2020-02-14 重庆市畜牧科学院 Application of FSH and HCG in preparation of medicine for promoting testicular cell function recovery

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5929028A (en) * 1997-01-15 1999-07-27 Akzo Nobel, N.V. Liquid gonadotropin containing formulations
US20040204393A1 (en) * 2001-04-17 2004-10-14 Casper Robert F. Aromatase inhibition to enhance assisted reproduction
US20040224895A1 (en) * 1999-05-07 2004-11-11 Applied Research Systems Ars Holding N.V. Gonadotrophins
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
WO2007056851A1 (en) * 2005-11-17 2007-05-24 Mount Sinai Hospital Compositions and methods for enhancing ovulation inducing agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5929028A (en) * 1997-01-15 1999-07-27 Akzo Nobel, N.V. Liquid gonadotropin containing formulations
US20040224895A1 (en) * 1999-05-07 2004-11-11 Applied Research Systems Ars Holding N.V. Gonadotrophins
US20040204393A1 (en) * 2001-04-17 2004-10-14 Casper Robert F. Aromatase inhibition to enhance assisted reproduction
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
WO2007056851A1 (en) * 2005-11-17 2007-05-24 Mount Sinai Hospital Compositions and methods for enhancing ovulation inducing agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PLOMAN ET AL.: "Endotoxin Levels and Mouse Embryo Development in Two Commercially Available IVF media.", ABSTRACTS OF THE 12TH ANNUAL MEETING OF THE EHSRE, 1996, MAASTRICHT *

Also Published As

Publication number Publication date
WO2012127501A2 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
WO2012127501A3 (en) Composition for improving endometrial thickness during ovarian stimulation
UA99337C2 (en) Liquid formulation of fsh
WO2017100726A8 (en) Methods for treating huntington's disease
WO2011041694A3 (en) Compounds as lysophosphatidic acid receptor antagonists
WO2011017350A3 (en) Compounds as lysophosphatidic acid receptor antagonists
WO2011041461A3 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011062437A3 (en) Gonadotropin releasing hormone receptor antagonists, manufacturing method thereof, and pharmaceutical composition containing same
WO2010077882A3 (en) Antagonists of lysophosphatidic acid receptors
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
WO2010068775A3 (en) Alkyne antagonists of lysophosphatidic acid receptors
WO2009130198A3 (en) Hyperglycosylated human coagulation factor ix
MY153976A (en) Lh liquid formulations
JO3122B1 (en) Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, processes for their preparation, pharmaceutical preparations comprising them and their use for preparing medicaments
IN2015DN00528A (en)
IN2011KN05169A (en)
MX342098B (en) Pharmaceutical preparation containing selenite or selenite-containing compounds for treating cervical dysplasia or carcinomas.
HRP20150968T4 (en) Composition for use in treating infertility
WO2015054649A3 (en) Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
MX362905B (en) Combination treatment.
IN2014DN09240A (en)
GB2530226A (en) Chewable tablet
MX2012015102A (en) Therapeutic agents 976.
NZ609804A (en) Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
WO2012127500A3 (en) Composition for spermatogenesis
WO2009075838A3 (en) Treatment of menorrhagia with aromatase inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12760525

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12760525

Country of ref document: EP

Kind code of ref document: A2